MedTrace Logo

A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis

NCT03614078 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2020-03-30

Study results available
· View outcomes & findings →

Summary

The aim of this study is to evaluate safety, tolerability, and efficacy of PRCL-02 in moderate to severe chronic plaque psoriasis

Conditions

Interventions

DRUG

PRCL-02

Oral tablets

DRUG

Placebo

Oral tablets

Sponsors & Collaborators

  • PRCL Research Inc.

    lead OTHER

Principal Investigators

  • Study Director · PRCL Research Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-25
Primary Completion
2019-04-29
Completion
2019-07-08
FDA Drug
Yes

Countries

  • Canada
  • Slovakia
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03614078 on ClinicalTrials.gov